Post #12 by LucidDreamer on the Esperion Therapeutics board

Please be respectful of others' privacy, and avoid sharing personal information or sensitive content without their permission. If you are unsure if something is appropriate to share, ask for permission (use the 'Privately email' option when replying to their post) or avoid sharing it altogether.

- Manlobbi

Stocks A to Z / Stocks E / Esperion Therapeutics (ESPR)

Unthreaded | Threaded | Whole Thread (2)

Prev | Next

Post New | Post Reply | Report Post | Recommend It!

No. of Recommendations: 3

not sure if related or not, but stock up 56% (as of this typing) from about $1.60 to $2.54 since Oct 1st or so.

European partner growing strong (DSE).
Otsuka partner for Japan almost ready to start selling now (2025 start) which triggers milestones and royalties.

They should address Nov 2025 Note soon.

At ER conf call last week they mention partnership for Canada is imminent.

US sales up 50% Y/Y.
Scripts up 46% Y/Y which is 4th straight Q of a minimum 42% Y/Y growth.

US sales on pace for $120m in 2024.

Market Cap is still only 500m????

Do your own DD and invest accordingly.

Dreamer

Post New | Post Reply | Report Post | Recommend It!

Print the post

Unthreaded | Threaded | Whole Thread (2)

Prev | Next

Announcements

Esperion Therapeutics FAQ

Contact Shrewd'm
Contact the developer of these message boards.

A community forum supporting civilized, and highly helpful, self-educating investors that come together for Shrewdness and merry spirits. These message boards closely follow the look and feel of the old message boards at boards.fool.com prior to the boards redirected to discussion.fool.com. Shrewd'm is not affiliated with the comprehensive and excellent investment website, The Motley Fool (TMF), in any way. The Shrewd commmunity here has owed, and continues to owe, gratitude to The Motley Fool for nurturing a culture of jovial irreverence towards Wall St, and that tradition will continue here.